Compare AUROW & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUROW | VCEL |
|---|---|---|
| Founded | 2017 | 1989 |
| Country | United States | United States |
| Employees | 1900 | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 1.7B |
| IPO Year | N/A | 1996 |
| Metric | AUROW | VCEL |
|---|---|---|
| Price | $0.30 | $38.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $57.75 |
| AVG Volume (30 Days) | 43.1K | ★ 524.0K |
| Earning Date | 04-30-2025 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | N/A | $19.40 |
| Revenue Next Year | N/A | $18.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $0.13 | $28.95 |
| 52 Week High | $1.08 | $43.57 |
| Indicator | AUROW | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 41.80 | 65.58 |
| Support Level | $0.17 | $32.47 |
| Resistance Level | $0.42 | $42.04 |
| Average True Range (ATR) | 0.09 | 1.56 |
| MACD | -0.02 | 0.42 |
| Stochastic Oscillator | 0.00 | 98.58 |
Aurora Innovation is a US autonomous driving provider for heavy trucks. The company produces and sells its Aurora Driver system, which includes hardware installed in a vehicle, software to autonomously drive it, and data management to maintain and improve the software. Aurora targets long-haul routes. The company currently offers its trucking-as-a-service model, where it owns and operates the trucks and makes deliveries for customers. The company plans to start selling its driver-as-a-service model next year, where fleet owners will own the trucks and Aurora's software will operate them.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.